Scholarlink

The evolutionary processes that neoplastic cells undergo to develop mechanisms of resistance toward anticancer drugs are complex and diverse. They are acquired through genomic alterations that range from chromosomal rearrangements to single nucleotide variations and their translation into pre-clinical experimental models is crucial to unveil the pathways involved and identify new actionable targets. For this purpose, CRISPR/Cas9 technology has become a useful tool thanks to its ability to generate different types of mutations. However, its implementation requires a series of choices and optimization steps based on the experimental system to be utilized. In this review, we offer a detailed overview of the key features of this technology and how it should be adapted to the needs of the researcher to successfully model drug resistance within the oncology field.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Implementing CRISPR/Cas9 into the Study of Anticancer Drug Resistance

  • 章节

  • 发表日期：

    2024年

查看全文
  • Marc Terrones,
  • Ken Op de Beeck,
  • Guy Van Camp,
  • Geert Vandeweyer

摘要

The evolutionary processes that neoplastic cells undergo to develop mechanisms of resistance toward anticancer drugs are complex and diverse. They are acquired through genomic alterations that range from chromosomal rearrangements to single nucleotide variations and their translation into pre-clinical experimental models is crucial to unveil the pathways involved and identify new actionable targets. For this purpose, CRISPR/Cas9 technology has become a useful tool thanks to its ability to generate different types of mutations. However, its implementation requires a series of choices and optimization steps based on the experimental system to be utilized. In this review, we offer a detailed overview of the key features of this technology and how it should be adapted to the needs of the researcher to successfully model drug resistance within the oncology field.